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Introduction: We previously showed that pharmacokinetic-guided prophylaxis (PKP) allows the dosing interval to
be extended while maintaining a specific trough level. However, the associations of peak factor VIII (FVIII) levels
and area under the curve (AUC) with breakthrough bleeding have not been investigated. Aim: The aim of this
study was to analyse data from the PKP arm to determine whether peak FVIII levels, AUC and time with FVIII
levels in a haemostatically effective range are independent predictors of bleeding during prophylaxis. Methods:
Post hoc analysis of the association of FVIII levels and AUC with annualized bleeding rate in 34 patients on PKP.
Results: During 1 year of PKP, 131 bleeding episodes occurred in 24/34 patients. Average peak FVIII levels
ranged from 24 to 168 IU dL1, with higher values associated with a decreased risk for all bleeding (joint and
non-joint; P < 0.01) and joint bleeding (P < 0.01). Following rFVIII infusion, median percent of time spent with
FVIII levels >20 IU dL1 was 22%; median AUC was 1363. Both values were significantly associated with a
lower ABR when targeting a 1% trough at 72 h. Conclusion: When PKP was administered every third day,
higher peak FVIII levels, higher AUC and more time spent per week with FVIII levels >20 IU dL1 provided
increased protection from joint and non-joint bleeding. These data highlight the potential impact of variability in
individual pharmacokinetic and bleeding risk and support the need for high peak levels and AUC in some
patients treated every third day. The findings do not necessarily apply to alternate-day or other prophylactic
dosing regimens.
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Introduction
Prophylaxis is considered optimal care for children and
adults with severe haemophilia A [1,2] because of its
proven ability to reduce joint and other bleeding epi-
sodes [3–7]. On the basis of experience from Sweden,
where prophylaxis was pioneered in the late 1950s [8],
target factor VIII (FVIII) trough levels for prophylaxis
have traditionally been set at ≥1 IU dL1 above
baseline, with the intent of converting the severe bleed-
ing phenotype into the less frequent bleeding pattern
of moderate haemophilia [9]. Yet 1 IU dL1 is an arbi-
trary value above which neither all haemorrhages are
prevented nor below which bleeding inevitably occurs
[10,11]. Some patients, including those with arthropa-
thy or who have active lifestyles, may require higher
FVIII trough levels [12], whereas others may have
trough levels lower than 1 IU dL1 but do not bleed
[3]. Furthermore, peak FVIII levels, area under the
curve (AUC) and time spent with FVIII levels
>15 IU dL1 [13]) may also be important in protecting
against haemarthroses and other bleeding episodes,
particularly during periods of high activity, when
patients are at increased risk for traumatic bleeding.
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A ‘one size fits all’ approach to prophylaxis is not
necessarily ideal, possibly leading to inefficient or
unnecessarily costly dosing. Using an individual’s
pharmacokinetic (PK) response to factor VIII (FVIII)
infusions to calculate dose and dosing frequency is
one strategy for personalizing the prophylactic regi-
men [12,14,15]. In the study of prophylaxis with
ADVATE Antihemophilic Factor (Recombinant),
Plasma/Albumin Free Method (rAHF-PFM)
(NCT00666406), PK-guided prophylaxis (PKP) given
every third day was comparable to standard weight-
based every-other-day prophylaxis (SP) [6]. In both
arms, the annualized bleeding rate (ABR) [6] and the
median annualized joint bleeding rate (AJBR) [16]
were significantly reduced as compared with on-
demand therapy (OD), and the PKP arm had the
advantage of requiring 1 less infusion weekly [6].
Here, we report the results of a post hoc analysis of
data for the intent-to-treat PKP group to determine
whether peak FVIII levels, AUC and time with FVIII
levels >20 IU dL1 are independent predictors of pro-
phylactic efficacy for patients using PKP every third
day.
Methods
Clinical study summary
The details of the rAHF-PFM prophylaxis study
(NCT00243386) have been described [6]. To sum-
marize, 66 previously on-demand-treated males with
moderately severe to severe haemophilia A (FVIII
≤2%) aged 7 to 59 years (median: 26 years) who
experienced ≥8 joint haemorrhages in the previous
year were treated OD for 6 months. These patients
(the intent-to-treat population) were then randomly
assigned to 12 months of SP (20–40 IU kg1 every
other day) or PKP (20–80 IU kg1 every third day),
with the PKP regimen intended to maintain FVIII
trough levels ≥1 IU dL1. All prophylactic doses
were to be infused in the morning. The characteris-
tics of the study patients were similar for the two
prophylaxis arms, with all but one patient in the SP
arm and two patients in the PKP arm having 1–10
target joints (defined as ≥4 bleeds into the same
joint within a 6-month period or >20 lifetime bleeds
into a joint) at the start of prophylaxis. (Five of 32
[16%] patients in the SP arm and 13/34 [38%] in
the PKP arm had experienced ≥3 joint bleeds in the
year preceding study randomization.) No informa-
tion was collected with regard to patients’ lifestyle
or physical activity.
Median (interquartile range [P25, P75]) ABR during
prophylaxis was 1.0 (0.0, 3.5) and 2.0 (0.0, 6.9) for
the SP and PKP arms, respectively, whereas the med-
ian ABR (IQR) during OD was 43.9 (34.6, 56.5), a
statistically significant difference (P < 0.0001) [6].
Twenty-two patients (33.3%) were haemorrhage-free
while receiving prophylaxis (either regimen), whereas
all patients experienced bleeding during the OD per-
iod. Similarly, the AJBR was significantly lower for
per protocol patients (n = 53) treated with SP (55
total haemarthroses; AJBR median: 0.48 [1.96]) or
PKP (72 total haemarthroses; AJBR median: 1.00
[4.07]), as compared with OD (1164 total haemar-
throses; AJBR median: 38.65 [24.81]; P < 0.0001)
[16]. Median (range) FVIII trough levels were
3.0 IU dL1 (0.5–45.0) during SP (56 observations in
24 patients) and 1.0 IU dL1 (0.5–10.0) during PKP
(52 observations in 23 patients). FVIII consumption
and adverse event rates for both prophylactic regimens
were equivalent, and no patient developed a hypersen-
sitivity reaction related to rAHF-PFM or a FVIII inhi-
bitor while on study.
Data for all 34 patients in the every third day
intent-to-treat PKP arm were evaluated. A total of
4089 prophylactic infusions were administered during
a median of 364 treatment days (range: 97–394). The
median dose per infusion was 43.0 (range: 13.0–
107.1) IU kg1, and the median number of units
administered per patient was 2979 (range: 1073–
5600). Bleeding episodes were recorded in patient dia-
ries and verified by the investigator. Data collected
included time and date of bleeding, anatomical site(s),
identification of bleeding as joint or non-joint, aetiol-
ogy (spontaneous, traumatic or undetermined) and
severity.
Statistical analyses
The predicted concentration level (IU dL1) at the
time of bleeding was projected on the basis of individ-
ual PK parameters, assuming that each patient was at
his natural baseline. Average peak FVIII levels were
estimated using individual in vivo recovery values and
average dose/prophylactic infusion.
A negative binomial multivariate regression model
was used to evaluate the association between ABR
and (i) average peak FVIII level (IU dL1), (ii) time
spent >20 IU dL1 FVIII activity (%) and 3) weekly
AUC (IU 9 h dL1); age and body mass index were
covariates [17]. ABR was calculated as the number of
bleeding events divided by the length (in years) of the
treatment regimen. Average peak FVIII level was cal-
culated as the average dose (IU kg1) during the study
multiplied by incremental recovery (IU dL1 IU1
kg1). Time spent and weekly AUC above 5, 10, 15,
20, 30 and 40 IU dL1 FVIII activity were estimated
from each patient’s infusion log and time per week
together with his PK parameters. Correlation between
two variables was described using non-parametric
spearman method.
© 2016 The Authors. Haemophilia Published by John Wiley & Sons Ltd. Haemophilia (2016), 22, 514--520
ASSOCIATION OF PEAK FVIII AND AUC WITH BLEEDING 515
Results
A total of 845 bleeding episodes (188 traumatic, 657
spontaneous; 750 joint, 95 non-joint) occurred in the
34 patients during 6 months of OD that preceded PKP.
The mean SD (range; median) ABR and AJBR during
on-demand treatment was 49.2  20.7 (13–90.8; 44.8)
and 43.5  21.3 (6.5–90.8; 39.0) respectively.
Number of haemorrhages and time of bleeding
During PKP, 131 bleeding episodes occurred in 24/34
patients (70.6%). Among the 121 episodes of joint
bleeding, 4 (all spontaneous) occurred within the first
12 h after infusion, 20 (6 spontaneous) occurred 12–
24 h post infusion, 49 (21 spontaneous) occurred 24–
48 h post infusion and 40 (20 spontaneous) occurred
48–72 h post infusion (Table 1). No significant
increase was observed in the number of bleeding
episodes occurring more than 48 h after infusion as
compared with those occurring within the first 48 h.
Pattern of spontaneous and traumatic bleeding
The median predicted concentration (range) at the time
of bleeding among patients in the PKP arm was
2.71 IU dL1 (0–26.55) for 57 spontaneous haemor-
rhages, 3.57 IU dL1 (0–41.6) for 74 traumatic haemor-
rhages, 3.43 IU dL1 (0–41.67) for 121 haemarthroses
and 2.87 IU dL1 (0–11.26) for 10 non-joint bleeding
events (Figs 1 and 2). No statistically significant differ-
ence in predicted FVIII levels was observed either
between spontaneous or traumatic or joint and non-joint
haemorrhages. Traumatic joint bleeding occurred with
predicted FVIII levels as high as 42%, but most haemar-
throses occurred at levels <10 IU dL1 (median
predicted value 3.43 [IQR = 7.18 [1.33–8.51]).
Peak levels and bleeding risk
Average peak FVIII levels (IVR 9 average dose) in the
PKP arm ranged from 24.3 to 167.5% (median:
70.9%), with lower values associated with an
increased risk for all bleeding (P = 0.0004) and joint
bleeding (P = 0.0013) (Fig. 3).
AUC and peak FVIII levels in non-bleeding and
bleeding patients
The average predicted AUC was 136 between 24 and
48 h and 33 between 48 and 72 h post infusion. To
further examine the possible relationship between high
AUC, peak FVIII levels and bleeding risk in the imme-
diate hours following infusion, we compared the
weekly AUC 0–12 h post infusion for patients who did
and did not report bleeding (Table 2). No significant
difference was observed between the two groups, likely
attributable to the small sample size. Nonetheless,
patients who had no bleeding during the 12-month
study period appeared to have higher post infusion
AUC 0–12 h as well as higher peak FVIII levels.
Time spent at FVIII levels >20 IU dL1 and
bleeding risk
Among patients in the PKP arm, the median percent of
time spent with FVIII levels >20 IU dL1 was 22.3%
Table 1. Number of haemorrhages (patients) and time at which bleeding
occurred post infusion in the pharmacokinetic-guided prophylaxis arm.
Bleeding type 12 h 12-24 h 24-48 h 48-72 h >72 h* All
Spontaneous 4 (4) 7 (4) 21 (13) 22 (12) 3 (3) 57
Traumatic 0 (0) 14 (9) 31 (10) 22 (11) 7 (4) 74
Joint 4 (4) 20 (11) 49 (17) 40 (15) 2 (1) 121
Non-joint 0 (0) 1 (1) 3 (2) 4 (3) 2 10
*Indicates non-adherence to the treatment regimen.
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Fig. 1. Spontaneous and traumatic bleeding
episodes over time in patients on pharmacoki-
netic-guided prophylaxis (PKP).
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(range: 2.9–46.1), resulting in a median AUC of 1363
(range: 130–4265). Both values were significantly asso-
ciated with a lower ABR, and during the period that the
FVIII concentration was ≥27 IU dL1, PKP-treated
patients experienced no spontaneous bleeding. This
relationship was even more pronounced when a higher
percentage of time was spent with FVIII levels
>30 IU dL1 (Fig. 4) or higher peak levels (Figs 1 and
2) were achieved. The modelled data showed a consis-
tent and strong positive correlation among peak level,
time above percent and weekly AUC (Table 3).
Discussion
In this post hoc analysis of the rAHF-PFM prophy-
laxis study data, patients receiving PKP every third
day were dosed to maintain a target trough FVIII level
of ≥1 IU dL1 [6], thereby eliminating time spent
<1 IU dL1 as a variable contributing to bleeding risk.
Evaluating PK parameters in relation to the reported
bleeding events led to three observations. First, higher
peak FVIII levels and AUC provided increased protec-
tion against joint and non-joint bleeding. Specifically,
spontaneous bleeding was prevented when patients in
the PKP arm had a FVIII concentration ≥27 IU dL1.
Broderick and colleagues similarly recognized the
link between high peak levels and a reduction in
bleeding [18]. In a case-crossover study nested within
a prospective cohort study that included 104 children
and adolescents with haemophilia, they found the
transient increase in bleeding risk associated with vig-
orous physical activity was mitigated with estimated
peak factor concentrations of 70–100 IU dL1.
Conversely, low peak levels may have contributed to
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Fig. 2. Joint/non-joint bleeding episodes over
time in patients on pharmacokinetic-guided
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Fig. 3. Average peak factor VIII (FVIII) levels
and risk for bleeding in patients on pharmacoki-
netic-guided prophylaxis (PKP). The trend curve
presents the predicted ABR derived from the nega-
tive binomial multivariate regression model across
the average peak FVIII level for an average patient
(with regard to age and body mass index). The
average peak FVIII levels are related to the risk of
all bleeding (P = 0.0004; coeff: 0.02) and joint
bleeding (P = 0.0013; coefficient: 0.02). Four
quadrants are identified to signify the relationship
between bleeding rates and average peak FVIII
levels. The horizontal line represents median ABR
(2.0) for the overall population, and the vertical
line represents median theoretical peak FVIII level
achieved following prophylactic infusion.
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the increase in bleeding events observed by Lindvall
et al. [19] in some patients who crossed over to daily
low-dose prophylaxis designed to maintain at least the
same FVIII trough level as obtained with their stan-
dard prophylactic regimens.
Second, ABR declined as the percent of time spent
weekly with FVIII levels >20–30 IU dL1 rose.
Specifically, among eight patients who spent ≥20%
of time about 30 IU dL1, only two had an ABR
>2. Nearly 40 years ago, Aronstam described a 60%
reduction in bleeding frequency in boys with severe
haemophilia A treated with FVIII-containing ‘materi-
als’ to increase their factor levels to 15–30% of
normal [20]. In 2011, den Uijl et al. observed that
patients with haemophilia A who had a baseline
FVIII activity exceeding 15 IU dL1 experienced no
joint bleeding [13]. This result is not directly
equivalent to the situation observed in our study,
however, as a steady state of 15 IU dL1 differs
from the peaks and troughs we described. In addi-
tion, our FVIII level data are modelled on the basis
of estimated PK parameters and patient-reported
infusion and bleed event (including aetiology)
records, which may introduce some degree of error.
Nevertheless, Broderick also noted the connection
between higher FVIII levels and bleed reduction,
reporting that the risk of bleeding decreased by 2%
for each 1% increase in factor activity [18]. When
factor levels were maintained at approximately
50 IU dL1 during physical activity, bleeding risk
was lower than that for inactive patients treated on-
demand.
Finally, while traumatic bleeding occurred through-
out the range of predicted FVIII plasma levels (as high
as 58 IU dL1), most occurred at FVIII levels
<10 IU dL1. These observations are consistent with
those reported by den Uijl et al. [13].
In patients with haemophilia A, joint bleeding
results in increased morbidity, decreased health-related
quality of life and higher treatment costs associated
with the management of chronic arthropathy [21–24].
Table 2. Peak factor VIII (FVIII) and area under the curve (AUC) levels within 12-h post infusion in non-bleeding and bleeding patients.
Non-bleeding patients (N = 9) Bleeding patients (N = 25)
P-value*Min Q25 Median Q75 Max Min Q25 Median Q75 Max
Average peak FVIII (IU dL1) 45.9 66.9 83.6 124.4 150.9 24.3 45.9 56.4 108.3 167.5 0.4793
Weekly AUC for 12 h after infusion 852.2 1134.5 1263.0 1846.0 2882.0 490.3 774.5 1097.5 1712.1 2353.4 0.3765
*P-value is from t-test.
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Table 3. Average peak level, time above % and weekly area under the
curve (AUC) covariance in the pharmacokinetic-guided prophylaxis (PKP)
arm: correlation coefficients among the variables.
Variable PKP (N = 34)
Time >5% AUC >5%
Time >10% AUC >10%
Time >20% AUC >20%
Time >30% AUC >30%
Time >40% AUC >40%
Average peak (IU dL1) ns 0.82 (s)
0.43 (s) 0.82 (s)
0.65 (s) 0.87 (s)
0.90 (s) 0.94 (s)
0.94 (s) 0.95 (s)
Time >5% Not applicable 0.60 (s)
Time >10% 0.81 (s)
Time >20% 0.90 (s)
Time >30%
Time >40% 0.99 (s)
Non-parametric correlation coefficient: (s) indicates P < 0.05.
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Prophylaxis is highly effective in preventing joint and
other serious bleeding episodes [3–6,25], but a person-
alized approach to treatment [15] that takes into
consideration an individual’s PK – FVIII peaks and
AUC as well as troughs – may have the potential to
optimize the treatment regimen.
It is important to recognize that the findings from
our analyses are specific to patients with severe hae-
mophilia A (baseline FVIII ≤2%) receiving PKP
administered every third day. The results cannot nec-
essarily be extrapolated to other regimens and may
not be applicable to alternate-day dosing. Indeed, we
have previously reported that AUC was not associated
with breakthrough bleeds in patients receiving prophy-
laxis three to four times per week [26]. Furthermore,
almost all patients had pre-existing joint disease, with
nearly 40% having ≥3 target joints at study initiation.
The impact of joint status on FVIII levels at the time
of bleeding is unclear. Finally, consistent with the
results of den Uijl et al. [13], the influence of peak
FVIII levels is likely to diminish as baseline FVIII
levels approach the normal range.
The observation that lower peak levels were associ-
ated with increased bleeding in the PKP arm has inter-
esting implications. Patients with the longest-half-lives
required the lowest FVIII doses to sustain a level
>1 IU dL1 by 72 h and, therefore, also had the low-
est peaks. Thus, paradoxically, those with the longest
half-lives appeared to do less well on every third day
prophylaxis targeted at a trough of 1 IU dL1 than
did those with shorter half-lives. In addition, owing to
the shape of the PK curves in people with longer half-
lives, those with lower peaks also spent more time
with low FVIII levels between infusions. Whether
these findings have implications for more frequent
dosing intervals and/or for treatment with extended
half-life molecules require further investigation.
Limitations to the analysis
Our analysis has several limitations. First, the data set
is comprised of only 34 patients receiving PKP, and
the analysis was performed post hoc. Second, informa-
tion about FVIII activity at the time of each bleeding
episode was extrapolated from PK data obtained at
study entry and was calculated using patient-reported
time of infusion and time of haemorrhage without
adjustment for potential residual FVIII from prior
dose. Third, the impact of a patient’s lifestyle and par-
ticipation in sports activities on bleeding could not be
ascertained, as these data were not collected, but it is
possible that they may have influenced bleeding in
some patients. Finally, the possibility that some joint
pain-related events may have been misclassified as
haemarthroses, and that some bleeding episodes may
not have been recognized or were misclassified as
traumatic (vs. spontaneous) cannot be ruled-out.
In conclusion, the findings from this post hoc analy-
sis of data for the PKP arm of the rAHF-PFM prophy-
laxis study add to previous observations that time
spent with FVIII levels <1% positively correlates with
bleeding risk by demonstrating that in patients receiv-
ing every third day prophylaxis targeting a trough of
1 IU dL1, peak FVIII levels, AUC and time spent at
high FVIII plasma levels are also associated with the
risk for joint and non-joint bleeding. The data high-
light the potential impact of variability in individual
PK and the likelihood for haemorrhage and may sup-
port the need for higher peak levels and AUC in some
patients on every third day dosing, such as those with
underlying joint disease or during periods of increased
activity. These conclusions do not necessarily apply to
patients receiving alternate-day dosing, and further
studies in this group are needed.
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